Investor directory

CHL Medical Partners

CHL Medical Partners is a venture capital firm specializing in seed, start-up, and early stage investments. The firm typically invests in healthcare sector with a focus on biotechnology, molecular healthcare services, and life sciences tools and services. It targets companies focusing on consumer convenience including consumer healthcare and elder care, companies providing specialized service or a new care setting including general hospitals, companies addressing shortfall of access to care and providing efficient solutions to the administration of healthcare, service and product businesses specializing in new technology, drugs, and medical device. It primarily invests in companies based in the Continental United States. The firm initially invests between $0.1 million and $7.5 million and can invest up to $15 million over the life of the investment. It also provides follow-on-financing and helps in raising additional capital in public and private markets. The firm prefers to be the lead investor and builds a long-term syndicate of co-investors. It seeks board representation in its portfolio companies. The firm takes an interim management role in its seed investments. The firm exits its investments through the acquisition of its portfolio companies by multiple strategic, financial, and public buyers. CHL Medical Partners was founded in 1997 and is based in Southport, Connecticut.

Focus

PharmaceuticalsHealth CareHealth DiagnosticsHealthcare and BiotechMedicalShow more
http://chlmedical.com
https://crunchbase.com/organization/chl-medical-partners
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=19741

49 past transactions

Amicus Therapeutics

Series D in 2006
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

GeneOhm Sciences

Series C in 2005
GeneOhm Sciences designs, develops, and delivers nucleic acid-based diagnostic solutions. It focuses on serving the unmet diagnostic needs in a wide range of diseases including inherited disease, infectious disease and oncology. It is developing rapid, nucleic acid-based systems that will detect and identify infectious agents and genetic variations. GeneOhm Sciences is dedicated to offering laboratories and clinical scientists cutting-edge, FDA-approved, molecular based tests that can provide results in less than two hours. Established in San Diego, California in 2001, GeneOhm Sciences merged with Infectio Diagnostic, Inc. of Québec, Canada in 2004. The integrated company combines an extensive portfolio of proprietary technology, strong industry expertise and capabilities with an experienced and accomplished management team to lead the way. Most of GeneOhm’s development focus is on the applications electric current flowing through DNA as a means to detect genetic mutations. GeneOhm was recently acquired by the BD Pharmaceuticals group.

Protometrix

Seed Round in 2001
Protometrix develops integrated proteomics technologies to improve human health. Protometrix focuses on the production and investigation of the function and interaction of proteins in parallel using nanoscale technology and collection of information in an informatics database.

GeneOhm Sciences

Series C in 2004
GeneOhm Sciences designs, develops, and delivers nucleic acid-based diagnostic solutions. It focuses on serving the unmet diagnostic needs in a wide range of diseases including inherited disease, infectious disease and oncology. It is developing rapid, nucleic acid-based systems that will detect and identify infectious agents and genetic variations. GeneOhm Sciences is dedicated to offering laboratories and clinical scientists cutting-edge, FDA-approved, molecular based tests that can provide results in less than two hours. Established in San Diego, California in 2001, GeneOhm Sciences merged with Infectio Diagnostic, Inc. of Québec, Canada in 2004. The integrated company combines an extensive portfolio of proprietary technology, strong industry expertise and capabilities with an experienced and accomplished management team to lead the way. Most of GeneOhm’s development focus is on the applications electric current flowing through DNA as a means to detect genetic mutations. GeneOhm was recently acquired by the BD Pharmaceuticals group.

Ambra Health

Series A in 2010
Ambra Health is a medical data and image management SaaS company. Intuitive, flexible, scalable and highly interoperable, the Ambra cloud platform is designed to serve as the backbone of imaging innovation and progress for healthcare providers. It empowers some of the largest health systems such as Memorial Hermann, Stanford Children’s Health and New England Baptist Hospital as well as radiology practices, subspecialty practices and clinical research organizations to dramatically improve imaging and collaborative care workflows. As expert partners, we listen to our customers, understand their needs, and apply our extensive knowledge to deliver innovative medical image management solutions for the future of healthcare, now.

RxCentric

Series B in 2000
RxCentric is an e-health business-to-business company linking physicians' drug information and education needs with a targeted, online.

Lifespire

Venture Round in 2000
Lifespire was created in late 1999 through the merging of 2 companies: Vida Healthcare and inspiria.com. Vida Healthcare, formed in 1996, has worked with hundreds of oncology doctors, nurses and allied health professionals to improve cancer care. Lifespire Their vision is to improve care through shared knowledge. But what does that mean to you, the patient, and your circle of family and friends They serve? It means that They are giving you and the ones closest to you -- your circle of care -- a resource for gathering credible knowledge, support and understanding of your experience with cancer. Some of you may have known us when They were Vida Healthcare. In Their four years as Vida, They delivered clinical support and education services to over 4,000 people experiencing cancer. Now They're bringing that experience and understanding to you. They're doing this in partnership with companies committed to improving the treatment of cancer. And They're using Lifespire.com as Their forum for delivery.

PrimeraDx (Primera Biosystems)

Series C in 2009
PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.

North American Scientific

Venture Round in 2008
North American Scientific is engaged in the design, development, manufacture, and sale of radioisotopic products for the treatment of cancer. The company offers Prospera I-125, an iodine-based seed and Prospera Pd-103, a palladium-based seed for the treatment of prostate cancer; SurTRAK needles and strands used primarily for the treatment of prostate cancer; and STP-110 Precision Stepper and RTP-6000 Precision Stabilizer equipment, which positions and holds the trans-rectal ultrasound probe during the LDR brachytherapy procedure as well as radiation shielding and needle loading accessories such as horizontal needle box; and needle-loading shield, box, and carousel. The company also offers ClearPath, a multi-catheter breast brachytherapy device for accelerated partial breast irradiation treatment for women with early-stage breast cancer. North American Scientific was founded in 1987 and is based in Chatsworth, California, United States.

VaxInnate

Series A in 2002
VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

Valeritas

Series C in 2011
On June 30, 2020, Valeritas Holdings, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

Millennium Pharmacy Systems

Venture Round in 2007
Millennium Pharmacy Systems is a pharmacy services provider to the long-term care industry. Offering a new approach to pharmacy services, Millennium delivers on the promise of "the right drug, for the right patient, at the right time, for the right price" so its customers can deliver the best patient care while reducing costs, and more easily meeting compliance demands. Only Millennium combines Just-In-Time Dispensing with electronic medication and treatment ordering, administration, documentation, and reporting. Millennium backs up the commitment with delivery timeliness and medication accuracy customer guarantees. Millennium is headquartered in Chicago, Illinois.

Mevion Medical Systems

Private Equity Round in 2014
Mevion Medical Systems, Inc. develops proton therapy systems for use in the radiation treatment of cancer patients. It serves customers worldwide. Mevion Medical Systems, Inc. was formerly known as Still River Systems, Inc. and changed its name to Mevion Medical Systems, Inc. in October 2011. The company was founded in 2004 and is based in Littleton, Massachusetts with additional offices in the United Kingdom, China, and Japan.

OpGen

Series B in 2010
OpGen, Inc is a privately-held company, based in Gaithersburg, MD, and focused on commercializing rapid, high precision solutions for DNA analysis and genomics with the Argus® Whole Genome Mapping System and MapIt® Services. Using the proprietary technologies provided by OpGen, customers in academic, government, biodefense and research labs as well as premier genome centers around the world can view ordered whole genome maps for a wide range of applications including strain typing for early outbreak response, improved sequence assembly of microbial and now large genomes up to 3 Gb and comparative genomics applications. OpGen Community (Linkedin Group) provides an accessible environment to share information, exchange questions and best practices using OpGen’s technologies in a variety of applications.

POINT Biomedical

Private Equity Round in 2008
POINT Biomedical is a privately held pharmaceutical company, founded to pursue technologies related to imaging and drug delivery. POINT's core technology is based upon an ultrasonically responsive two-layer, biodegradable microsphere or biSphereâ„¢. One of the most important features of this technology is the ability to noninvasively trigger the biSpheres to release their contents at sites within the body using externally generated pulses of ultrasound. From this basic platform, POINT is developing a pipeline of products that leverage the unique properties of the biSphere technology in the areas of imaging and therapeutics. POINT has initially focused development of this platform on the assessment of tissue specific blood flow. The lead product, CARDIOsphereâ„¢, is a pharmaceutical agent that will enable cardiologists to perform myocardial perfusion imaging studies in the office setting using ultrasound rather than more expensive and cumbersome nuclear (or radioisotope) techniques

Vertos Medical

Series D in 2010
Vertos Medical is a healthcare company that offers medical devices used in the treatment of common spinal diseases. The company commercializes the percutaneous treatment for lumbar spinal stenosis (LSS). It also offers minimally invasive lumbar decompression devices for the treatment of various forms of LSS. The company offers its devices in the United States. Vertos Medical, Inc. was founded by Dr. Dave Solsberg and Dr. Don Schomer in 2005 and is headquartered in Aliso Viejo, California, USA.

Amicus Therapeutics

Series A in 2002
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

RxCentric

Series C in 2001
RxCentric is an e-health business-to-business company linking physicians' drug information and education needs with a targeted, online.

VaxInnate

Series C in 2006
VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

BioRelix

Series A in 2007
BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.

Mevion Medical Systems

Private Equity Round in 2013
Mevion Medical Systems, Inc. develops proton therapy systems for use in the radiation treatment of cancer patients. It serves customers worldwide. Mevion Medical Systems, Inc. was formerly known as Still River Systems, Inc. and changed its name to Mevion Medical Systems, Inc. in October 2011. The company was founded in 2004 and is based in Littleton, Massachusetts with additional offices in the United Kingdom, China, and Japan.

OpGen

Series C in 2012
OpGen, Inc is a privately-held company, based in Gaithersburg, MD, and focused on commercializing rapid, high precision solutions for DNA analysis and genomics with the Argus® Whole Genome Mapping System and MapIt® Services. Using the proprietary technologies provided by OpGen, customers in academic, government, biodefense and research labs as well as premier genome centers around the world can view ordered whole genome maps for a wide range of applications including strain typing for early outbreak response, improved sequence assembly of microbial and now large genomes up to 3 Gb and comparative genomics applications. OpGen Community (Linkedin Group) provides an accessible environment to share information, exchange questions and best practices using OpGen’s technologies in a variety of applications.

OpGen

Venture Round in 2007
OpGen, Inc is a privately-held company, based in Gaithersburg, MD, and focused on commercializing rapid, high precision solutions for DNA analysis and genomics with the Argus® Whole Genome Mapping System and MapIt® Services. Using the proprietary technologies provided by OpGen, customers in academic, government, biodefense and research labs as well as premier genome centers around the world can view ordered whole genome maps for a wide range of applications including strain typing for early outbreak response, improved sequence assembly of microbial and now large genomes up to 3 Gb and comparative genomics applications. OpGen Community (Linkedin Group) provides an accessible environment to share information, exchange questions and best practices using OpGen’s technologies in a variety of applications.

RxCentric

Series D in 2002
RxCentric is an e-health business-to-business company linking physicians' drug information and education needs with a targeted, online.

Threshold Pharmaceuticals

Series B in 2004
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

Ascend Health

Series B in 2007
Ascend Health Corporation is a behavioral healthcare provider, offering a full range of inpatient and day hospital services to children, adolescents, adults and seniors. They focus on personal choice and specialized care. Their facilities provide high quality care by working closely to integrate their services with the healthcare system in each local community.

Mevion Medical Systems

Series C in 2007
Mevion Medical Systems, Inc. develops proton therapy systems for use in the radiation treatment of cancer patients. It serves customers worldwide. Mevion Medical Systems, Inc. was formerly known as Still River Systems, Inc. and changed its name to Mevion Medical Systems, Inc. in October 2011. The company was founded in 2004 and is based in Littleton, Massachusetts with additional offices in the United Kingdom, China, and Japan.

VaxInnate

Series B in 2004
VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

Oculir

Series A in 2005
Oculir develops non-invasive glucose meter that measures glucose from the conjunctiva of the eye.

Vertos Medical

Series C in 2008
Vertos Medical is a healthcare company that offers medical devices used in the treatment of common spinal diseases. The company commercializes the percutaneous treatment for lumbar spinal stenosis (LSS). It also offers minimally invasive lumbar decompression devices for the treatment of various forms of LSS. The company offers its devices in the United States. Vertos Medical, Inc. was founded by Dr. Dave Solsberg and Dr. Don Schomer in 2005 and is headquartered in Aliso Viejo, California, USA.

VaxInnate

Series D in 2009
VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

ICOS Corporation

Venture Round in 1990
ICOS Corporation is a biotechnology company that engages in the discovery, development, and commercialization of therapeutic products. It is engaged in the commercialization of treatments for unmet medical conditions, such as benign prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. It is the developer of a treatment known as Cialis (tadalafil), a product for the treatment of erectile dysfunction through its joint venture with Eli Lilly and Company in North America and Europe. It is also engaged in contract manufacturing services for third parties. It is in a strategic alliance with Solvay Pharmaceuticals, Inc. ICOS Corporation was established in 1989, based in Bothell, Washington. It is currently operated by Eli Lilly and Company.

Spine Wave

Series D in 2007
Spine Wave, Inc. manufactures and markets medical equipment for the treatment of spinal disorders. It offers expandable PEEK spacers and expandable interbody devices for posterior surgery; pivoting spacer systems; lateral spacer systems, XDL expandable devices, and lateral access systems for lateral stabilization; Leva PX, an expandable interbody device for the treatment of spinal disorders; GraftMag Graft Delivery System to deliver large amounts of bone graft; and fixation products, such as spine systems for treating degeneration, deformity, tumor, and trauma of the thoracolumbar spine, as well as adjacent level systems. The company also offers anterior cervical plate systems that provide stabilization as an adjunct to spinal fusion from C2-C7 through anterior screw fixation; and cervical spacer systems to treat degenerative disc disease from C2-T1. It offers its products through distributors. Spine Wave, Inc. was founded in 2001 and is based in Shelton, Connecticut.

Resolvyx Pharmaceuticals

Series A in 2005
Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.

Vascular Pathways

Debt Financing in 2014
Vascular Pathways, founded by Amir Belson, M.D., is a privately held medical device company focused on commercializing the Rapid IntraVascular Start (RIVS) catheter, an FDA cleared device enabling rapid, safe and successful peripheral IV insertion.

Molecular Staging

Series D in 2000
Molecular Staging, Inc., a life sciences tool company, develops technologies for the detection and measurement of proteins and nucleic acids. It provides technologies for proteomics, genomics, pharmacogenomics, and diagnostics applications. The company’s products and services include protein microarrays analogous to the DNA microarray, enabling researchers to study multiple proteins; whole-genome amplification that allows DNA samples as resources, enabling researchers to return to them for new tests or confirmatory diagnoses; and multiplexed diagnostics that enable earlier detection of disease.

Bikam Pharmaceuticals

Series A in 2007
BIKAM Pharmaceuticals is a drug discovery company focused on the discovery and development of novel drugs for degenerative diseases. It discovers and develops pharmacologic chaperones for misfolded proteins within the retina that lead to serious retinal degenerative disease and blindness, including retinitis pigmentosa and dry age-related macular degeneration. BIKAM Pharmaceuticals was founded in 2007 and is based in Cambridge, Massachusetts.

Mevion Medical Systems

Venture Round in 2009
Mevion Medical Systems, Inc. develops proton therapy systems for use in the radiation treatment of cancer patients. It serves customers worldwide. Mevion Medical Systems, Inc. was formerly known as Still River Systems, Inc. and changed its name to Mevion Medical Systems, Inc. in October 2011. The company was founded in 2004 and is based in Littleton, Massachusetts with additional offices in the United Kingdom, China, and Japan.

Amicus Therapeutics

Series C in 2005
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

CareWell Urgent Care

Series A in 2012
CareWell Urgent Care operates emergency health care centers in the New England area. Its approach to urgent care includes on-site labs, x-ray capabilities, and dispensing of common medications. CareWell Urgent Care is based in Tewksbury, Massachusetts.

Spine Wave

Series C in 2006
Spine Wave, Inc. manufactures and markets medical equipment for the treatment of spinal disorders. It offers expandable PEEK spacers and expandable interbody devices for posterior surgery; pivoting spacer systems; lateral spacer systems, XDL expandable devices, and lateral access systems for lateral stabilization; Leva PX, an expandable interbody device for the treatment of spinal disorders; GraftMag Graft Delivery System to deliver large amounts of bone graft; and fixation products, such as spine systems for treating degeneration, deformity, tumor, and trauma of the thoracolumbar spine, as well as adjacent level systems. The company also offers anterior cervical plate systems that provide stabilization as an adjunct to spinal fusion from C2-C7 through anterior screw fixation; and cervical spacer systems to treat degenerative disc disease from C2-T1. It offers its products through distributors. Spine Wave, Inc. was founded in 2001 and is based in Shelton, Connecticut.

Ambra Health

Series B in 2012
Ambra Health is a medical data and image management SaaS company. Intuitive, flexible, scalable and highly interoperable, the Ambra cloud platform is designed to serve as the backbone of imaging innovation and progress for healthcare providers. It empowers some of the largest health systems such as Memorial Hermann, Stanford Children’s Health and New England Baptist Hospital as well as radiology practices, subspecialty practices and clinical research organizations to dramatically improve imaging and collaborative care workflows. As expert partners, we listen to our customers, understand their needs, and apply our extensive knowledge to deliver innovative medical image management solutions for the future of healthcare, now.

Amicus Therapeutics

Series B in 2004
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Cantex Pharmaceuticals

Series B in 2006
Cantex Pharmaceuticals is a biotechnology company engaged in harnessing known therapies to develop novel and safer cancer treatments. Cantex is currently conducting two unique development programs with modified versions of two separate known chemical entities each of which addresses major unmet medical needs representing high-value market opportunities:

Vascular Pathways

Series B in 2010
Vascular Pathways, founded by Amir Belson, M.D., is a privately held medical device company focused on commercializing the Rapid IntraVascular Start (RIVS) catheter, an FDA cleared device enabling rapid, safe and successful peripheral IV insertion.

Mevion Medical Systems

Venture Round in 2012
Mevion Medical Systems, Inc. develops proton therapy systems for use in the radiation treatment of cancer patients. It serves customers worldwide. Mevion Medical Systems, Inc. was formerly known as Still River Systems, Inc. and changed its name to Mevion Medical Systems, Inc. in October 2011. The company was founded in 2004 and is based in Littleton, Massachusetts with additional offices in the United Kingdom, China, and Japan.

Resolvyx Pharmaceuticals

Series B in 2008
Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.

Millennium Pharmacy Systems

Venture Round in 2005
Millennium Pharmacy Systems is a pharmacy services provider to the long-term care industry. Offering a new approach to pharmacy services, Millennium delivers on the promise of "the right drug, for the right patient, at the right time, for the right price" so its customers can deliver the best patient care while reducing costs, and more easily meeting compliance demands. Only Millennium combines Just-In-Time Dispensing with electronic medication and treatment ordering, administration, documentation, and reporting. Millennium backs up the commitment with delivery timeliness and medication accuracy customer guarantees. Millennium is headquartered in Chicago, Illinois.